{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:51:51Z","timestamp":1777765911606,"version":"3.51.4"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Patients with inflammatory bowel disease (IBD) are at increased risk of major adverse cardiovascular events (MACE), driven by chronic inflammation, endothelial dysfunction, and use of certain therapeutic regimens. Whether different IBD treatments mitigate this risk remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the association of the use of immunomodulators or biologics vs 5-aminosalicylic acid (5-ASA) with risk of MACE among older patients with IBD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This comparative effectiveness study was conducted among a 15% Medicare claims sample of patients with IBD aged 65 years or older was identified, with entry defined by the first prescription of immunomodulators, biologics, or 5-ASA between January 1, 2012, and December 31, 2020. Follow-up extended to the outcome, switch or discontinuation of study drug, the study\u2019s administrative end, or up to 3 years, whichever occurred first. Propensity score matching at a 1:3 ratio balanced demographics, comorbidities, and medication use between groups. Data analyses were conducted between January and September 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Exposures were use of immunomodulators or biologics compared with 5-ASA, identified using National Drug Codes and Healthcare Common Procedure Coding System procedure codes.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was time to the first emergency department or inpatient visit caused by a MACE, defined as myocardial infarction, stroke, or all-cause mortality. Hazard ratios (HRs) and 95% CIs for MACE risk with immunomodulators or biologics vs 5-ASA were estimated using Cox proportional hazards models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 16\u202f387 patients (mean [SD] age, 74.73 [6.79] years; 9861 [60.18%] female) were included in the analysis. In the immunomodulators vs 5-ASA and biologics vs 5-ASA cohort, the mean (SD) ages were 74.05 (6.43) years and 73.68 (6.01) years, respectively, after matching. Both cohorts had more female participants (2580 [58.85%] and 1780 [58.09%], respectively). Baseline comorbidities were mostly balanced between groups. Compared with 5-ASA, there was no statistically significant difference in the risk of MACE for immunomodulators (HR, 0.84 [95% CI, 0.61-1.17]) or biologics (HR, 0.86 [95% CI, 0.59-1.24]), although point estimates were below 1.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this comparative effectiveness study of Medicare beneficiaries with IBD, there was no statistically significant difference in MACE risk between those who used immunomodulators or biologics vs 5-ASA.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.9091","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:30:26Z","timestamp":1777476626000},"page":"e269091","source":"Crossref","is-referenced-by-count":0,"title":["Immunomodulators, Biologics, and 5-ASA for Inflammatory Bowel Disease and Major Adverse Cardiovascular Events in Older Adults"],"prefix":"10.1001","volume":"9","author":[{"given":"Qi","family":"Jian","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naueen A.","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, College of Medicine, University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanxing","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, College of Medicine, University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianze","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"3","key":"zoi260282r1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pop.2023.03.009","article-title":"Inflammatory bowel disease.","volume":"50","author":"Bruner","year":"2023","journal-title":"Prim Care"},{"key":"zoi260282r2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review.","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"zoi260282r3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16859","article-title":"A review of four practice guidelines of inflammatory bowel disease.","volume":"13","author":"Okobi","year":"2021","journal-title":"Cureus"},{"key":"zoi260282r4","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"4","key":"zoi260282r5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1756283X11405250","article-title":"Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease.","volume":"4","author":"Williams","year":"2011","journal-title":"Ther Adv Gastroenterol"},{"key":"zoi260282r6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.897936","article-title":"Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease.","volume":"9","author":"Marsal","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"zoi260282r7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.5009\/gnl19209","article-title":"Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries.","volume":"14","author":"Banerjee","year":"2020","journal-title":"Gut Liver"},{"issue":"12","key":"zoi260282r8","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease.","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"zoi260282r9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.cgh.2017.02.005","article-title":"Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel disease: a meta-analysis.","volume":"15","author":"Qiu","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi260282r10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/01.MIB.0000209787.19952.53","article-title":"Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD.","volume":"12","author":"van Dieren","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"zoi260282r11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.amjmed.2022.08.012","article-title":"Inflammatory bowel disease and cardiovascular diseases.","volume":"135","author":"Chen","year":"2022","journal-title":"Am J Med"},{"issue":"1","key":"zoi260282r12","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeab029","article-title":"Inflammatory bowel disease and cardiovascular diseases: a concise review.","volume":"2","author":"Wu","year":"2021","journal-title":"Eur Heart J Open"},{"issue":"6","key":"zoi260282r13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032775","article-title":"Inflammatory bowel disease and associated cardiovascular disease outcomes: a systematic review.","volume":"102","author":"Jaiswal","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"zoi260282r14","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.cgh.2018.04.031","article-title":"Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases.","volume":"16","author":"Aniwan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"28","key":"zoi260282r15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehae338","article-title":"Risk of heart failure in inflammatory bowel disease: a Swedish population-based study.","volume":"45","author":"Sun","year":"2024","journal-title":"Eur Heart J"},{"key":"zoi260282r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101456","article-title":"Association between inflammatory bowel disease and atrial fibrillation: a systematic review and meta-analysis.","volume":"53","author":"Goyal","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"zoi260282r17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejim.2020.02.029","article-title":"Atrial fibrillation in patients with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"76","author":"Zuin","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"2","key":"zoi260282r18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056944","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death\u2014a Danish nationwide cohort study.","volume":"8","author":"Kristensen","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"zoi260282r19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/ibd\/izy354","article-title":"Risk of myocardial infarction in inflammatory bowel disease: a population-based national study.","volume":"25","author":"Panhwar","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"zoi260282r20","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.cgh.2023.05.014","article-title":"Patients with microscopic colitis are at higher risk of major adverse cardiovascular events: a matched cohort study.","volume":"21","author":"Forss","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi260282r21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10238-020-00639-y","article-title":"The risk of cardiovascular complications in inflammatory bowel disease.","volume":"20","author":"Czubkowski","year":"2020","journal-title":"Clin Exp Med"},{"key":"zoi260282r22","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2568569","article-title":"Vascular endothelial dysfunction in inflammatory bowel diseases: pharmacological and nonpharmacological targets.","volume":"2018","author":"Gravina","year":"2018","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"zoi260282r23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/jgh.12260","article-title":"Venous and arterial disease in inflammatory bowel disease.","volume":"28","author":"Tan","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"zoi260282r24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis.","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"zoi260282r25","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211023399","article-title":"The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.","author":"Hong","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"zoi260282r26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"15","key":"zoi260282r27","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.3390\/jcm11154422","article-title":"Safety of biological therapies in elderly inflammatory bowel diseases: a systematic review and meta-analysis.","volume":"11","author":"Hahn","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"zoi260282r28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"zoi260282r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gloepi.2022.100080","article-title":"A practical guide to handling competing events in etiologic time-to-event studies.","volume":"4","author":"Mansournia","year":"2022","journal-title":"Glob Epidemiol"},{"key":"zoi260282r30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1349636","article-title":"Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.","volume":"15","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"issue":"11","key":"zoi260282r31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4330\/wjc.v15.i11.553","article-title":"Cardiovascular implications of inflammatory bowel disease: An updated review.","volume":"15","author":"Bhardwaj","year":"2023","journal-title":"World J Cardiol"},{"key":"zoi260282r32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970597","article-title":"Analysis of clinical characteristics of mesalazine-induced cardiotoxicity.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"issue":"15","key":"zoi260282r33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/eurjpc\/zwad124","article-title":"Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population.","volume":"30","author":"Sleutjes","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"zoi260282r34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2023.11.005","article-title":"Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies.","volume":"232","author":"Papa","year":"2023","journal-title":"Thromb Res"},{"issue":"16","key":"zoi260282r35","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.3390\/diagnostics14161722","article-title":"Cardiovascular risk in patients with inflammatory bowel diseases\u2014the role of endothelial dysfunction.","volume":"14","author":"Livzan","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"zoi260282r36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate: studies in healthy volunteers and patients with rheumatoid arthritis.","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"zoi260282r37","first-page":"1024","article-title":"Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases.","volume":"17","author":"Balanescu","year":"2019","journal-title":"Exp Ther Med"},{"issue":"3","key":"zoi260282r38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1179\/1351000213Y.0000000046","article-title":"Free radicals and endothelial dysfunction: potential positive effects of TNF-a inhibitors.","volume":"18","author":"Murdaca","year":"2013","journal-title":"Redox Rep"},{"issue":"17","key":"zoi260282r39","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","article-title":"Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.","volume":"106","author":"H\u00fcrlimann","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"zoi260282r40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.RES.0000229685.37402.80","article-title":"Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome.","volume":"99","author":"Picchi","year":"2006","journal-title":"Circ Res"},{"issue":"17","key":"zoi260282r41","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-integrin therapy for inflammatory bowel disease.","volume":"24","author":"Park","year":"2018","journal-title":"World J Gastroenterol"},{"key":"zoi260282r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105050","article-title":"Controlling leukocyte trafficking in IBD.","volume":"159","author":"Veny","year":"2020","journal-title":"Pharmacol Res"},{"issue":"3","key":"zoi260282r43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension.","volume":"25","author":"Hoorn","year":"2012","journal-title":"J Nephrol"},{"key":"zoi260282r44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.981838","article-title":"Cardiovascular effects of immunosuppression agents.","volume":"9","author":"Elezaby","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"zoi260282r45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pdi.2209","article-title":"Tacrolimus.","volume":"36","author":"Biddle","year":"2019","journal-title":"Pract Diabetes"},{"issue":"1","key":"zoi260282r46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.kint.2024.10.015","article-title":"Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases.","volume":"107","author":"Canney","year":"2025","journal-title":"Kidney Int"},{"issue":"7","key":"zoi260282r47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101709","article-title":"Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization.","volume":"9","author":"Pr\u00fcfer","year":"2014","journal-title":"PLoS One"},{"issue":"9313","key":"zoi260282r48","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"zoi260282r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.100991","article-title":"Advanced biologic therapies and cardiovascular events in patients with inflammatory bowel disease.","volume":"22","author":"Chaaban","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"11","key":"zoi260282r50","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1007\/s10620-022-07388-w","article-title":"Real-world insurance claims analysis of venous thromboembolism in Japanese patients with inflammatory bowel disease.","volume":"67","author":"Fujiya","year":"2022","journal-title":"Dig Dis Sci"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848255\/jian_2026_oi_260282_1776801450.62182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:30:27Z","timestamp":1777476627000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.9091","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}